Fig. 3.

Laboratory tests with sex-specific RIs ordered in calendar year 2021 on patients documented to be on either estradiol or testosterone gender-affirming therapy at the time of laboratory testing. The bar graphs indicate how often these tests were within sex-specific RIs for both sexes (light blue), abnormal in both intervals (red), or abnormal in only one sex-specific interval (yellow) using the patient age at time of laboratory testing. (A) Analysis for patients receiving estradiol as gender-affirming therapy at the time of laboratory testing (2919 laboratory tests on 423 unique patients). (B) Analysis for patients receiving testosterone as gender-affirming therapy at the time of laboratory testing (2743 laboratory tests on 469 unique patients). Abbreviations and reference intervals are the same as described in Fig. 2. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)